Video

Understanding Supportive Services in Lung Cancer

As a part of its Speaking Out Video series, CURE® spoke with Terri Conneran, on behalf of KRAS Kickers, about supportive services for lung cancer.

Related Videos
Image of a man in a suit.
Image of man with black hair.
Image of man with gray hair.
Dr. Kelly Stratton
Related Content
Subcutaneous Keytruda plus berahyaluronidase alfa meets phase 3 trial end points in non–small cell lung cancer.
November 21st 2024

Subcutaneous Keytruda Plus Berahyaluronidase Alfa Combo Meets Phase 3 Trial End Points in NSCLC

Ryan Scott
Treatment with subcutaneous Keytruda plus berahyaluronidase alfa meets phase 3 trial end points in the treatment of metastatic non–small cell lung cancer.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of a woman with short blonde hair, wearing a colorful striped shirt.
November 19th 2024

Why Clinical Trials Don’t Have to Be Patients’ ‘Last Line of Defense’

Alex Biese
A patient with small cell lung cancer shared her clinical trial experience with CURE® and how she encourages other patients with cancer to enroll.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Blue background with the FDA logo.
November 16th 2024

FDA Receives Application for Dato-DXd Treatment in EGFR-Mutated NSCLC

Ryan Scott
For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated approval of Dato-DXd.
Illustration of lungs.
November 15th 2024

Anti-TIGIT Therapy-Based Treatment Combo Did Not Improve Survival in Extensive-Stage SCLC

Caroline Seymour
The anti-TIGIT therapy, vibostolimab, plus Keytruda and chemotherapy did not improve overall survival versus Tecentriq plus chemotherapy in extensive-stage small cell lung cancer.